- The potential continuation in diabetes and obesity trends may provide positive long-term tailwinds for Novo.
- With health experts now urging Americans to get tested for diabetes at age 35 vs. 40, a potential increase in diagnoses could create a short-term catalyst.
- Novo's current drug and treatment pipeline may provide the support necessary for management's goal of reaching 1/3 of the total diabetes treatment market share.
- Between dividends and share buybacks, I believe management has shareholders' best interests in mind regarding capital distribution.
For further details see:
Novo Nordisk: Dominance In The Diabetes Market